Johnson & Johnson Innovation Opens JLABS @ NYC
06/25/2018
JLABS @ NYC can accommodate up to 30 biotech, pharmaceutical, medical device, consumer and health tech companies and opens with 26 resident companies, including the four winners of the JLABS @ NYC QuickFire Challenge.
"Johnson & Johnson has deep entrepreneurial roots in New York and we are pleased to see our unique JLABS model applied in this rich ecosystem to foster the creation of new healthcare innovations that have the potential to change the trajectory of health for humanity," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "Expanding our JLABS network to NYC will link entrepreneurs around the region with Johnson & Johnson Innovation experts, allowing some of the brightest minds in healthcare to work collaboratively in a shared space."
"This new 21st century incubator supports our efforts to boost economic growth by investing in cutting-edge research and technologies that advance human health," Governor Cuomo said. "By investing in JLABS @ NYC, we're connecting early-stage companies with the tools, resources, and networks to succeed while enhancing the life sciences industry and fostering job growth across New York."
"For too long, patients and consumers have not fully benefited from the incredible genius throughout the world. NYC and its environs are home to some of the greatest minds in scientific innovation, whose skills and their spirit have so much to offer," said Melinda Richter, Global Head of JLABS at Johnson & Johnson Innovation. "JLABS provides those innovators the environment they need to deliver life-enhancing, life-saving solutions to the people who need them. By opening up vital industry connections, entrepreneurial programs and a capital-efficient, flexible platform to help alleviate the cost burden that typically slows or kills innovation, we know NYC will light up our world."
"The New York Genome Center is honored to partner with Johnson & Johnson Innovation and New York State to bring the JLABS network to New York, further strengthening the life sciences sector," said Cheryl A. Moore, NYGC President & COO. "NYGC works to translate genomic research into new diagnostic tools and treatments for human disease, which is in perfect harmony with JLABS' vision of providing a platform to support emerging companies in transforming scientific discoveries into breakthrough healthcare products. We are excited to see the future developments from JLABS @ NYC and we appreciate the Governor's leadership and support in advancing life sciences infrastructure in New York."
JLABS facilities have incubated more than 370 companies to date, advancing biotech, pharmaceutical, medical device, consumer and health tech programs. JLABS @ NYC will follow the same no-strings-attached approach across all JLABS locations: San Diego; San Francisco; South San Francisco; Boston; Lowell, MA; Houston; Toronto; Beerse, Belgium; and Shanghai.
Project Announcements
Forge Construction Relocates-Expands Kansas City, Missouri, Headquarters Operations
03/23/2026
Henkel Plans Trumbull, Connecticut, Research-Development Operations
03/23/2026
BorgWarner Plans Hendersonville, North Carolina, Manufacturing Operations
03/23/2026
Altec Expands Mount Airy, North Carolina, Production Operations
03/23/2026
Ericson Manufacturing Expands Willoughby, Ohio, Operations
03/23/2026
Shintech Louisiana Expands Iberville Parish, Louisiana, Operations
03/22/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Amazon’s First Mass Timber Delivery Station Tests the Future of Low-Carbon Logistics
Q4 2025
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026